Autres langues Alector, Inc.

Actions

ALEC

US0144421072

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:49:20 29/09/2026			Varia. 5j.	Varia. 1 janv.
1,885 ^USD	-1,82%		-6,22%	+20,83%

16/09	Novartis interrompt le développement d'un traitement contre la SLA après l'échec d'un essai de phase intermédiaire	RE
15/09	Transcript : Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM

Autres langues

16/09	Novartis halts ALS drug development after mid-stage trial failure
03/09	Alector to Participate in Upcoming Healthcare Conferences
07/08	Alector : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
06/08	Alector: Q2 Earnings Snapshot
06/08	Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
09/07	Afternoon Meeting: Wall Street ignora las alarmas
09/07	Wall Street Ignores the Sirens
09/07	GSK adds Royal Philips' Chief Executive Jakobs to board
09/07	Öl hält die Märkte in Atem
09/07	Oil keeps markets on edge
09/07	UK Stocks-Factors to watch on July 9
08/07	Alector and GSK partnership to end after dementia, Alzheimer's drug failures
08/07	Alector, Inc. Announces Termination of Collaboration Agreement with Glaxo Wellcome UK Limited
08/07	Alector LLC and Alector, Inc. Repay $10,428,827.77 Aggregate Principal Amount Of Loans Under Loan And Security Agreement With Hercules Capital, Inc
08/05	Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Alector: Q1 Earnings Snapshot
07/05	Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Alector Reports First Quarter 2026 Financial Results and Provides Business Update
29/04	Alector to discontinue phase 2 trial of nivisnebart
29/04	Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
29/04	Alector Inc Discontinues Phase 2 Progress-Ad Trial of Nivisnebart and Provides Pipeline Update
15/04	Alector Shares Rise After Cantor Fitzgerald Upgrade
25/03	Alector : March 2026 Corporate Presentation
12/03	Alector Files $400 Million Mixed Shelf